Tenderwize
Zurück zur Suche

Open-house biologics rebate agreement for Epoetin beta

Techniker Krankenkasse·Hamburg, Germany·Deadline Jan 30, 2028 · 524 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-39 - Epoetin beta

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Supply-related pharmaceutical rebate agreement for Epoetin beta.
  • Open-house arrangement with uniform contractual conditions for all eligible participants.
Vollständige Zusammenfassung anzeigen

Open-house pharmaceutical supply arrangement for Epoetin beta in Germany, led by Techniker Krankenkasse with HEK and hkk as participating buyers. The notice states that any suitable pharmaceutical undertaking may join during the contract period, subject to the stated legal and self-declaration requirements. No contract value is provided. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the documents are only available electronically. The notice is in German and the extracted TED XML notice was analyzed, but no separate procurement document text was provided.

Risiken

The notice contains two different end-time references: structured data gives 2028-01-30 22:59:59 UTC, while the XML not...

Participation is limited to pharmaceutical undertakings meeting the AMG and authorisation conditions for the specific p...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal product(s).
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house biologics rebate agreement for Epoetin beta

Open-house contract for pharmaceutical rebate agreements under Section 130c(1) SGB V for the active substance Epoetin beta. The lot covers nationwide performance in Germany and is described as an open-house procedure with uniform conditions, no individual negotiations, and no exclusivity. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 30, 2028

Vergabedetails

Veröffentlichungsdatum
03 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
803675-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3